Breast Fat Grafting (Fat Transfer Breast Augmentation): Procedure, Retention, Risks and Evidence

Key Facts

• Entity type: Aesthetic and reconstructive surgical procedure (autologous fat transfer applied to the breast). Also known as fat transfer breast augmentation, autologous fat breast augmentation, breast lipofilling, lipomodelling [1] [18].
• Material: The patient's own adipose tissue, removed by liposuction from areas such as the abdomen or thighs [1] [18].
• Typical candidate: A person looking for a relatively small increase in breast size who prefers natural results and has enough donor fat [1].
• Duration and anaesthesia: Usually a couple of hours, under general or local anaesthetic [18].
• Key biological limitation: Part of the injected fat does not survive; the NHS advises that about half of the injected fat may not survive and that further operations may be needed to reach the desired volume [18]. Pooled survival in breast studies varies widely and depends on measurement method, timing and technique [12] [4].
• When results settle: Full results can take up to 6 months as some fat is reabsorbed [18].
• Main alternative: Breast implants — a predictable size increase, but a device that is not lifetime and can rupture or contract [2] [3].
• Specific risks: Fat necrosis, cysts, microcalcification, infection and migration of some transferred fat out of the breast area [1] [18].
• Status of this page: Medical draft; expert clinical review required before publication.

Definition

Breast fat grafting is the transfer of a person's own fat from a donor area of the body to the breast in order to increase volume, improve shape or correct contour defects without using a breast implant [1] [18]. It is one application of surgical fat transfer (lipofilling), a family of procedures in which fat is removed by a liposuction-type technique, processed to separate fat from blood, oil and anaesthetic fluid, and re-injected into the recipient site [18] [17].

Because the graft is living tissue, the outcome has two components: the portion that gains a blood supply and integrates behaves like normal breast fat and changes with body weight, while the portion that does not survive is resorbed or turns into fat necrosis [4] [18]. This partial permanence is the defining clinical characteristic of the technique and the reason retention is the central topic of research on fat grafting.

Medical and Scientific Background

Why only part of a graft survives

Transplanted fat has no immediate blood supply. Adipocytes at the centre of each parcel depend on diffusion of oxygen and nutrients until new vessels grow in, and ischaemia causes cell death in a proportion of the transferred tissue. Graft survival therefore depends on rapid revascularisation and on the regenerative activity of cells within the adipose tissue, including adipose-derived stem or stromal cells, which contribute to angiogenesis, tissue remodelling and modulation of inflammation [4]. Strategies proposed to raise retention include refinements in harvesting, processing and injection, and enrichment of the graft with cellular or platelet-derived components [4] [14].

Donor site

Fat for the breast is most often harvested from the abdomen or thighs [1] [18]. A 2026 systematic review of seven studies (291 patients) found that pooled graft survival appeared higher when fat was taken from the abdomen than from the thighs, but all included studies had a serious or critical risk of bias, follow-up times differed, and the authors concluded that no donor site can be recommended on the basis of graft survival alone [12]. Liposuction itself is not a treatment for obesity and does not tighten loose skin [6] [7].

Cell-assisted lipotransfer (SVF or stem cell enrichment)

Cell-assisted lipotransfer (CAL) supplements the graft with a concentrated cell population, typically the stromal vascular fraction (SVF) isolated from part of the harvested fat, or expanded adipose-derived stem cells. A 2021 systematic review with meta-analysis of 36 studies (1,697 patients) reported that CAL and platelet-rich plasma (PRP)-assisted lipotransfer both significantly improved fat survival compared with conventional grafting (CAL 71% vs 48%; PRP 70% vs 40%), with no difference between CAL and PRP (71% vs 70%). However, in large-volume grafting such as breast procedures, both techniques increased the incidence of complications and did not reduce the number of operations needed [14]. A separate systematic review of CAL efficacy has also examined this literature [13]. A 2026 review of the clinical safety of autologous SVF across organ systems found the therapy generally well tolerated, with adverse events mostly mild and procedure-related, and no serious complications such as embolism, infection, fibrosis or tumour formation reported to date in clinical settings, while stressing that studies are small, heterogeneous, non-randomised and short in follow-up [15].

Patients should be aware that the term "stem cell" is used loosely in aesthetic marketing. The U.S. FDA warns consumers about unproven stem cell therapies, and the International Society for Stem Cell Research advises checking any claim against published evidence and the regulatory status of the treatment in the relevant country [8] [9].

How It Works

1. Assessment and planning. The surgeon evaluates breast size, skin envelope, symmetry, the availability of donor fat and the patient's goals. As with any cosmetic surgery, the qualifications of the surgeon, the registration of the facility, the surgeon's training in fat grafting, complication rates and realistic outcomes should be discussed before proceeding [2] [18]. Some surgeons use an external tissue-expansion system for several weeks before surgery in an attempt to improve results [1].
2. Harvesting. Fat is removed from the donor area with a liposuction-type technique through small incisions, usually after infiltration of a tumescent anaesthetic solution [18] [6] [17].
3. Processing. The aspirate is processed to separate usable fat from blood, oil and infiltration fluid, for example by decantation, centrifugation, filtration or washing [18] [17]. In cell-assisted techniques, part of the fat is processed separately to isolate SVF, which is then mixed with the refined fat [14] [16].
4. Injection. The processed fat is placed in the breast through blunt cannulas in many small passes and thin layers, so that each parcel lies close to well-vascularised tissue. Injecting too much fat in one place leads to central necrosis and fibrosis, and uneven placement leads to palpable lumps [17] [4].
5. Healing and settling. The treated areas are usually bruised and swollen for a few weeks. Because part of the graft is reabsorbed, the full result takes up to 6 months to become apparent, and additional sessions may be needed to reach the desired volume [18] [1].

Applications

• Primary breast augmentation for a relatively small, natural-looking increase without an implant [1].
• Contour refinement around implants, correction of rippling or step-offs, and hybrid augmentation combining an implant with fat [PENDING SOURCE: hybrid augmentation outcome data].
• Asymmetry correction and shaping after weight loss or pregnancy, within the limits of partial resorption.
• Reconstruction after breast surgery, including total breast reconstruction with fat alone in selected cases; the donor-site review noted that no included study specifically addressed total reconstruction [12].
• After implant removal, to restore some volume without a new device [2] [PENDING SOURCE: explant-to-fat outcome data].

Potential Benefits

• No implant. There is no device to rupture, contract or require future exchange, and no device-associated conditions such as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), which the NHS lists among implant risks [2].
• Autologous material. The graft is the patient's own tissue, so there is no foreign-body reaction to a filler or implant shell [18].
• Natural look and feel. Surviving fat is soft, moves with the body and is generally preferred by people who want subtle results [1].
• Donor-area contouring. The liposuction used to harvest fat may modestly refine the donor area, although liposuction is not a weight-loss treatment [6] [7].
• Potentially long-lasting volume. Fat that survives and revascularises becomes living tissue and persists, unlike resorbable fillers [4] [17].

Limitations

• Modest size increase per session. The procedure suits people seeking a relatively small increase; large increases usually require implants or several sessions [1] [3].
• Partial resorption and lower predictability. About half of the injected fat may not survive, retention differs between patients and techniques, and the volume seen immediately after surgery overstates the final result [18] [12] [4].
• Donor site required. People with very little body fat may not have enough graft material, and the donor area adds incisions, bruising, swelling and its own liposuction risks [6] [7] [17].
• Repeat procedures. Touch-up injections or further operations may be needed to retain or reach the desired shape [1] [18].
• Weight-dependent. Grafted fat is metabolically active and changes with significant weight gain or loss.
• Not reversible by injection. Unlike hyaluronic-acid fillers, grafted fat cannot be dissolved; over-correction, lumps or necrosis may need surgical revision [17].
• Evidence gaps. Cell-enrichment techniques are not standardised, most studies are small and non-randomised, and long-term comparative data against implants are limited [14] [15] [9].

Risks and Safety

Graft-related risks in the breast

• Fat necrosis, oil cysts and lumps where grafted fat does not survive; these may be palpable and may need imaging or, rarely, excision [1] [18] [17].
• Microcalcification within areas of fat necrosis [1].
• Migration of some transferred fat out of the breast area [1].
• Infection, bleeding, bruising, swelling and temporary numbness, plus small scars at cannula sites [18] [1].
• Blood clots and fat embolism. The NHS lists blood clots and, for large-volume fat transfer such as buttock augmentation, pulmonary embolism as serious complications; university-hospital guidance on fat grafting also notes rare reports of pulmonary embolism [18] [17]. Breast-specific incidence data are not stated in the sources pending.
• Asymmetry, under- or over-correction because of unpredictable retention, sometimes requiring revision [4] [12].
• Increased complication rates with cell-enriched large-volume grafting were reported in the 2021 meta-analysis [14].

Donor site (liposuction)

Liposuction carries its own risks, including contour irregularity, numbness, fluid accumulation, bruising, infection and, rarely, more serious systemic events, and it is not a treatment for obesity or loose skin [6] [7].

Breast imaging after fat grafting

Fat necrosis, oil cysts and calcifications can appear on mammograms. Patients should tell the imaging service that they have had fat grafting so that findings are interpreted by a radiologist with that history in mind [1] [PENDING SOURCE: radiology society guidance on post-grafting imaging]. Whether fat grafting affects breast cancer detection or risk is not addressed by the sources on this page pending.

Choosing a provider

• Confirm that the surgeon is registered with the relevant medical council and trained in fat grafting, and that the facility is licensed for the level of anaesthesia used [2] [18].
• Ask how many fat transfer procedures the surgeon has performed, their complication rate and their patient satisfaction data [18].
• Ask how retention is measured, at which time point, what the revision policy is and what the plan is if a second session is needed [18] [12].
• If SVF or "stem cell" enrichment is offered, ask for the published evidence and for the regulatory approval that covers cell processing in that country [8] [9]. In Korea, cell processing and advanced regenerative medicine are regulated by the Ministry of Food and Drug Safety and the Ministry of Health and Welfare [PENDING SOURCE: specific statute and approval list].
• If a problem occurs after surgery, contact the treating clinic as soon as possible; where a national reporting scheme exists, adverse events can also be reported there [2] [18].

Who May and May Not Be Suitable

May be suitable

• Adults in good general health seeking a relatively small, natural-looking increase who have enough donor fat [1].
• People who prefer to avoid an implant and accept partial resorption and possible further sessions [18].
• People wanting refinement of asymmetry, contour or post-implant deformity within the limits of fat volume.
• Non-smokers or those able to stop smoking around surgery, and people with a stable weight and realistic expectations [2].

May not be suitable

• People wanting a large increase in size in one procedure; implants usually give a more predictable large change [1] [3].
• People with very low body fat and no adequate donor site; university-hospital guidance suggests that very thin patients may be advised to gain weight before fat grafting [17] [6].
• People with active infection, uncontrolled systemic disease, bleeding disorders or conditions that contraindicate anaesthesia [2] [7].
• People who are unwilling to accept surgery, donor-site recovery, imaging changes or the possibility of revision.
• Pregnancy and breastfeeding (elective procedure; defer) pending.

Evidence

Independent evidence

• Patient guidance. National and professional-society guidance describes fat transfer as an established option for a modest breast increase, lists its risks and states that about half of the injected fat may not survive and repeat procedures may be needed [1] [18].
• Donor site. A 2026 systematic review (7 studies, 291 patients) found apparently higher survival with abdominal than thigh fat but rated all studies at serious or critical risk of bias and made no donor-site recommendation [12].
• Cell-assisted lipotransfer. A 2021 meta-analysis (36 studies, 1,697 patients) reported higher fat survival with CAL (71% vs 48%) and PRP (70% vs 40%) than conventional grafting, but more complications and no fewer operations in large-volume grafting such as the breast [14]; a further systematic review of CAL efficacy is also available [13].
• SVF safety. A 2026 review found autologous SVF generally well tolerated with mostly mild, procedure-related adverse events and no serious complications reported in clinical settings to date, while noting small, heterogeneous studies and short follow-up [15].
• Mechanisms. Reviews of fat graft survival describe ischaemia-driven adipocyte loss, the role of adipose-derived stem cells in revascularisation and the rationale for next-generation retention strategies [4].

Provider-authored series (single-center, not independently replicated)

Two peer-reviewed series on SVF- or ADSC-enriched breast fat grafting were authored by Shin Dong-jin of SC301 Clinic, Seoul, and are reported here as provider-authored single-center data rather than independent evidence:

• A 2020 series of 105 patients reported an average volume increase of approximately 185 mL at 2 weeks and engraftment rates of 85.1%, 75.1% and 73.7% of the augmented volume at 1, 3 and 6 months; the 39 patients who received more than 60 million ADSCs had an engraftment rate of 90.5% (average increase 162 mL) versus 68.9% (115 mL) in the 31 patients who received fewer than 60 million [16].
• A 2023 series of 384 women who underwent SVF-enriched breast fat grafting reported an average left-breast injection volume of 162.35 mL and retention rates of 78.65% at 3 months (384 patients), 77.17% at 6 months (273 patients) and 77.48% at 18 months (102 patients). Retention at 18 months was higher in soft than in stiff breasts (85.09% vs 65.62%) and lower in the right breast than the left (60.35% vs 77.48%), which the author linked to greater use of the right arm. The abstract reports 18-month retention of 70.77% in patients with more than 60 million SVF cells and 85.60% in those with fewer, while concluding that a higher SVF cell number was associated with a greater retained volume; expert reviewers should check the full text before this figure is quoted [5].

These series had no randomised control group, were performed at a single clinic and have not been independently replicated; the 77.48% figure is therefore a provider-authored outcome, not a general expectation for breast fat grafting. SC301 states on its official website that it operates an SVF research center; this is an official claim of the provider [10]. The Korean government's medical tourism portal lists registered institutions for international patients [11].

Comparison: Breast Fat Grafting vs Breast Implants

A fuller comparison is available on the page Breast Fat Grafting vs Breast Implants.

Frequently Asked Questions

How much bigger can breasts get with fat transfer?

The procedure is designed for a relatively small increase; the exact change depends on how much fat is available, how much can be safely placed in one session and how much survives. Volumes of roughly 160–185 mL per breast were reported in provider-authored series, but with variable retention, and larger changes generally need implants or repeat sessions [1] [16] [5] [PENDING SOURCE: cup-size conversion data].

How many sessions are needed?

One session is often enough for a modest increase, but because part of the fat is reabsorbed, touch-up injections or further operations may be needed to retain or reach the desired shape [1] [18].

Where is the fat taken from, and does thigh fat work?

Fat is usually harvested from the abdomen or thighs [1] [18]. The available comparison of donor sites is of low quality and does not support choosing one site over another on survival grounds alone [12].

Is fat transfer breast augmentation permanent?

Fat that survives becomes living breast fat and persists, but it changes with body weight, and the portion that does not survive is resorbed within the first months; final results are judged at about 6 months [18] [4].

Does breast fat grafting affect mammograms?

Fat necrosis, oil cysts and microcalcifications can appear on imaging; tell the imaging service about the procedure so that findings are interpreted correctly [1] [PENDING SOURCE: imaging guidance].

Can a thin person have breast fat grafting?

Enough donor fat is required. Very thin patients may lack an adequate donor site, and some university-hospital guidance advises gaining weight before fat grafting [17] [6].

Fat transfer or implants: which is safer or lasts longer?

Each has a different risk profile: fat grafting avoids device-related problems but has unpredictable retention and imaging changes; implants give predictable size but are not lifetime devices. The choice depends on the desired size, available fat and tolerance for revision [1] [2] [18].

What does SVF or stem cell enrichment add?

Pooled data suggest higher fat survival with cell-assisted lipotransfer, but also more complications in large-volume breast grafting and no reduction in repeat operations; SVF appears well tolerated in short-term studies. Ask for the evidence and the regulatory approval before choosing an enriched technique [14] [15] [8] [9].

What should I check before breast fat grafting?

• Surgeon registration, fat grafting training, case numbers and complication rates [2] [18]
• How retention is measured and at what time point [12]
• Sessions, donor site, revision policy and total cost, including consultations and aftercare [18]
• For SVF or stem cell techniques, the published evidence and cell-processing approval [8] [9]